Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2γ transcription factor

Cancer Research

Volumn 64, Issue 22, 2004, Pages 8256-8261

  Aqeilan, Rami I ^a   Palamarchuk, Alexey ^a   Weigel, Ronald J ^b   Herrero, Juan J ^c   Pekarsky, Yuri ^a   Croce, Carlo M ^a,d  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c AxCell Biosciences   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 GAMMA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN WWOX; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE; DNA PRIMERS; DNA-BINDING PROTEINS; HUMANS; MICE; OXIDOREDUCTASES; PROTEIN BINDING; SUBCELLULAR FRACTIONS; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS;

EID: 8544283814     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2055     Document Type: Article

References (39)

1. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 2000;60:2140-5.
2. Ried K, Finnis M, Hobson L, et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000;9:1651-63.
3. Richards RI. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet 2001;17:339-45.
4. Ludes-Meyers JH, Bednarek AK, Popescu NC, Bedford M, Aldaz CM. WWOX, the common chromosomal fragile site, FRA16D, cancer gene. Cytogenet Genome Res 2003;100:101-10.
5. Paige AJ, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 2001;98:11417-22.
6. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002;62:2258-60.
7. Yendamuri S, Kuroki T, Trapasso F, et al. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 2003;63:878-81.
8. Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004;10: 2459-65.
9. Aqeilan R, Kuroki T, Pekarsky Y, et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004;10:3053-8.
10. Huebner K, Croce CM. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 2003;88:1501-6.
11. Driouch K, Prydz H, Monese R, Johansen H, Lidereau R, Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene 2002;21:1832-40.
12. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res 2001;61:8068-73.
13. Ilsley JL, Sudol M, Winder SJ. The WW domain: linking cell signalling to the membrane cytoskeleton. Cell Signalling 2002;14:183-9.
14. Macias MJ, Wiesner S, Sudol M. WW and SH3 domains, two different scaffolds to recognize proline-rich ligands. FEBS Lett 2002;513:30-7.
15. Kallberg Y, Oppermann U, Jornvall H, Persson B. Short-chain dehydrogenases/ reductases (SDRs). Eur J Biochem 2002;269:4409-17.
16. Oppermann U, Filling C, Hult M, et al. Short-chain dehydrogenases/ reductases (SDR): the 2002 update. Chem Biol Interact 2003;143-4:247-53.
17. Aqeilan RI, Pekarsky Y, Herrero JJ, et al. Functional association between Wwox tumor suppressor protein and p73, a p53 homolog. Proc Natl Acad Sci USA 2004; 101:4401-6.
18. Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001;276:3361-70.
19. Chang NS, Doherty J, Ensign A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem 2003;278:9195-202.
20. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000;260:1-12.
21. Tummala R, Romano RA, Fuchs E, Sinha S. Molecular cloning and characterization of AP-2 epsilon, a fifth member of the AP-2 family. Gene 2003;321:93-102.
22. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996;35:262-4.
23. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995;92:744-7.
24. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996;13:1701-7.
25. deConinck EC, McPherson LA, Weigel RJ. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 1995;15:2191-6.
26. McPherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA 1997;94:4342-7.
27. Guler G, Uner A, Guler N, et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004;100:1605-14.
28. Hu H, Columbus J, Zhang Y, et al. A map of WW domain family interactions. Proteomics 2004;4:643-55.
29. Ludes-Meyers JH, Kil H, Bednarek AK, Drake J, Bedford MT, Aldaz CM. WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 2004;23:5049-55.
30. Pellikainen J, Kataja V, Ropponen K, et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res 2002;8: 3487-95.
31. Eloranta JJ, Hurst HC. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem 2002;277:30798-804.
32. Muller S, Matunis MJ, Dejean A. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 1998;17: 61-70.
33. Minty A, Dumont X, Kaghad M, Caput D. Covalent modification of p73α by SUMO-1: two-hybrid screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 interaction motif. J Biol Chem 2000;275:36316-23.
34. Werling U, Schorle H. Transcription factor gene AP-2 γ essential for early murine development. Mol Cell Biol 2002;22:3149-56.
35. Jager R, Werling U, Rimpf S, Jacob A, Schorle H. Transcription factor AP-2γ stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res 2003;1:921-9.
36. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997;15:78-82.
37. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP2α mediated through a direct interaction with p53. J Biol Chem 2002;277:45028-33.
38. Turner BC, Zhang J, Gumbs AA, et al. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 1998;58:5466-72.
39. Zhao C, Yasui K, Lee CJ, et al. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003;98:18-23.